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Abstract
Accumulation of advanced glycation end products (AGEs) in joints is important in the development of cartilage destruction
and damage in age-related osteoarthritis (OA). The aim of this study was to investigate the roles of peroxisome proliferator-
activated receptor c (PPARc), toll-like receptor 4 (TLR4), and receptor for AGEs (RAGE) in AGEs-induced inflammatory
signalings in human OA chondrocytes. Human articular chondrocytes were isolated and cultured. The productions of
metalloproteinase-13 and interleukin-6 were quantified using the specific ELISA kits. The expressions of related signaling
proteins were determined by Western blotting. Our results showed that AGEs enhanced the productions of interleukin-6
and metalloproteinase-13 and the expressions of cyclooxygenase-2 and high-mobility group protein B1 and resulted in the
reduction of collagen II expression in human OA chondrocytes. AGEs could also activate nuclear factor (NF)-kB activation.
Stimulation of human OA chondrocytes with AGEs significantly induced the up-regulation of TLR4 and RAGE expressions
and the down-regulation of PPARc expression in a time- and concentration-dependent manner. Neutralizing antibodies of
TLR4 and RAGE effectively reversed the AGEs-induced inflammatory signalings and PPARc down-regulation. PPARc agonist
pioglitazone could also reverse the AGEs-increased inflammatory signalings. Specific inhibitors for p38 mitogen-activated
protein kinases, c-Jun N-terminal kinase and NF-kB suppressed AGEs-induced PPARc down-regulation and reduction of
collagen II expression. Taken together, these findings suggest that AGEs induce PPARc down-regulation-mediated
inflammatory signalings and reduction of collagen II expression in human OA chondrocytes via TLR4 and RAGE, which may
play a crucial role in the development of osteoarthritis pathogenesis induced by AGEs accumulation.
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Introduction
Osteoarthritis (OA) is a progressive degenerative joint disease
with signs and symptoms of inflammation, including joint pain,
swelling, and stiffness leading to significant functional impairment
and disability in older adults [1]. Cartilage damage in OA is
caused by the disruption of a shift in the balance between catabolic
and anabolic capacities of chondrocytes. Catabolic activities of OA
chondrocytes are related to the elevated release of cartilage
degrading enzymes, such as matrix metalloproteinases (MMPs),
while anabolic activities result in the productions of type II
collagen and aggrecan [2]. Several risk factors including obesity,
increasing age, trauma, genetic predisposition, and endocrine
factors are known to affect the progression of OA [3]. Aging has
been considered to be a major risk factor for OA [4]. Advanced
glycation end products (AGEs) produced irreversibly by the non-
enzymatic glycation of proteins have been observed to accumulate
with aging in various organs, especially in articular cartilage [5,6].
Accumulation of AGEs in cartilage chondrocytes shows the
decreased proteoglycan and collagen synthesis, which leads to
stiffness and brittleness of the articular cartilage [7]. Furthermore,
AGEs can also up-regulate the production of MMPs that mediate
cartilage degradation leading to the joint destruction [8]. In
chondrocytes of OA, AGEs has been shown to trigger the
expressions of interleukin (IL)-6 and IL-8 through receptor for
AGEs (RAGE) [9]. Activation of mitogen-activated protein kinase
(MAPK)-regulated NF-kB signaling was involved in this AGEs/
RAGE-induced expressions of IL-6 and IL-8 in chondrocytes [9].
On the other hands, toll-like receptor 4 (TLR4) has been shown to
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be up-regulated in the diabetic kidneys that the up-regulation of
TLR4 is associated with the TLR4 ligands AGEs and high-
mobility group protein B1 (HMGB1) in diabetic nephropathy
[10]. HMGB1 has also been found to induce the amplification of
inflammation and angiogenesis through TLRs and RAGE [11].
However, the role of TLR4 and RAGE in AGEs-induced
inflammatory signalings in human chondrocytes remains to be
clarified.
Peroxisome proliferator-activated receptors (PPARs) are ligand-
activated transcription factors and members of the nuclear
hormone receptor superfamily [12,13]. PPARc was originally
identified to play an important role in adipocyte differentiation
and lipid metabolism [14,15]. It has been shown that PPARc
signaling is involved in the metabolic disorders [16] and
cardiovascular diseases [17]. PPARc is known to be expressed in
many cell types including immune cells, endothelial cells,
synoviocytes, and chondrocytes [18–20]. PPARc expression has
been found to be decreased in human OA cartilage and down-
regulated in IL-1b-treated chondrocytes [21]. PPARc agonist
pioglitazone has also been demonstrated to be capable of
decreasing the progression of guinea pig OA [22]. Activation of
PPARc lead to the inhibition of various inflammatory signalings,
such as COX-2, IL-1b, IL-6 and TNFa, and MMP-1 expression
in monocytes as well as synoviocytes [18,19]. PPARc activators
have ability to prevent the inflammation-induced expressions of
iNOS, COX-2, and MMP-13 in human chondrocytes [20,23].
AGEs has recently been shown to down-regulate PPARc
expression in rabbit chondrocytes [24]. However, little is known
about the relationship among AGEs, RAGE, TLR4, and PPARc
in the pathogenesis of OA. Here, we tried to investigate the roles of
PPARc, TLR4, and RAGE in AGEs-induced inflammatory
signalings in human OA chondrocytes.
Materials and Methods
Ethics Statement
The samples of cartilage specimens were collected with written
approvals from the institutional Ethics Committee at National
Taiwan University Hospital, Taipei, Taiwan, and also from the
patients.
Reagents
Anti-mouse and anti-rabbit IgG-conjugated horseradish perox-
idase, rabbit polyclonal antibodies specific for RAGE, TLR4,
IkBa and Histone H1 were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal
antibodies specific for COX-2, collagen II, NF-kB p65, phos-
pho-JNK, JNK, phospho-ERK, ERK, phospho-p38MAPK,
p38MAPK, PPARc, b-actin, a-tubulin were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit
polyclonal antibody specific for phospho-IKKa/b (Ser180/181)
and phospho-p65 (Ser536) were purchased from Cell Signaling
(Danvers, MA, USA). Mouse monoclonal antibody specific for
RAGE was purchased from R&D Systems (Minneaplis, MN,
USA). MMP-13 and IL-6 ELISAs and mouse monoclonal
antibody specific for TLR4 were purchased from eBioscience.
NF-kB (p65) Transcription Factor Assay Kit was purchased from
Cayman Chemical Company (U.S.A). SB203580, SP600125,
PD98059, bovine serum albumin (BSA), pioglitazone, pyrrolidine
dithiocarbamate (PDTC) and all other chemicals were obtained
from Sigma-Aldrich (St. Louis, MO, USA).
Isolation and culture of chondrocytes from human
articular cartilage
Human articular chondrocytes were isolated from healthy
femoral head articular resected cartilage specimens and obtained
from 10 patients aged 50–76 years (mean age, 63.762.51 years)
who were generally healthy undergoing joint replacement surgery.
Cartilage pieces were minced finely, and chondrocytes were
isolated by sequential enzymatic digestion at 37uC with 0.2%
collagenase (type II; Sigma-Aldrich) for four hours in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco, Grand Island, NY).
Isolated chondrocytes were filtered through 100 mM nylon filters.
The cells were grown in the plastic cell culture dishes in 95% air–
5% CO2 with DMEM medium, which was supplemented with
20 mM HEPES and 10% heat-inactivated fetal bovine serum
(FBS), 2 mM glutamine, penicillin (100 U/ml), and streptomycin
(100 mg/ml) (pH adjusted to 7.4). Experiments were performed
using cells from passages 3–7. In experiments, chondrocytes were
plated in 6-well plates in complete DMEM medium and serum-
starved for 12 hours overnight and then treated with 5–100 mg/ml
AGEs for various time intervals in the presence or absence of
pharmacological inhibitors for MAPKs or NF-kB or neutralizing
antibodies for RAGE or TLR4. Chondrocytes cultured without
AGEs or with BSA alone were served as controls.
Preparation of AGEs
BSA (1 mg/ml) was incubated under sterile conditions with D-
glucose (1 mg/ml) in 0.2 M phosphate buffer (pH 7.4) at 37uC for
8 weeks. After incubation, AGEs were dialyzed against PBS for
24 hours to remove unbound sugars and filter-sterilized using a
0.22 mM Millipore filter (Millipore, Billerica, MA, USA). AGEs
were identified by Ultraflex III MALDI-TOF/TOF (Bruker) and
the AGEs protein concentration was measured by BCA protein
assay.
Cell viability assay
Cell viability was determined by 3-(4,5-dimethylthiazol- 2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma) assay. After
treatment of cells with or without AGEs or with BSA alone for
24 hours, cells were washed with PBS. MTT (0.2 mg/ml) was
then added to each well and the mixture was incubated for four
hours at 37uC. Culture medium was then replaced with an equal
volume of DMSO to dissolve blue formazan crystals. After the
mixture was shaken at room temperature for 10 minutes, the
absorbance was measured at 550 nm.
Measurement of IL-6 and MMP-13 productions
Human OA chondrocytes (16106/ml) cultured in 6-well plates
were stimulated with or without AGEs for 24 hours in the
presence or absence of pioglitazone. IL-6 and MMP-13 produc-
tions in the culture media were quantified by using the
commercially available IL-6 or MMP-13 specific ELISA kits
(eBioscience) according to the manufacturer’s instructions. The
plates were read at 450 nm.
Western blot analysis
The cellular lysates were prepared. Equal proteins (20–40 mg)
were resolved on SDS-PAGE and transferred to immobilon
polyvinyl difluoride (PVDF) membranes. The blots were blocked
with 4% BSA for one hour at room temperature and then probed
with the primary antibodies against COX-2, HMGB1, IkB kinase
(IKK)a/b, phospho-IKKa/b, IkBa, phospho-IkBa, p65, phos-
pho-p65, TLR4, phospho-ERK, phospho-p38MAPK, phospho-
JNK, collagen II, NF-kB p65, (1:1000, Santa Cruz) overnight at
AGEs Downregulate Chondrocyte PPARc via TLR4/RAGE
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4uC. After three washes, the blots were subsequently incubated
with the secondary goat anti-rabbit or anti-mouse antibodies
conjugated with horseradish peroxidase (1:1000) for one hour at
room temperature. The blots were visualized by enhanced
chemiluminescence using Kodak X-OMAT LS film (Eastman
Kodak, Rochester, NY).
Preparation of nuclear extracts and NF-kB activation
measurement
The binding activity of NF-kB to DNA was measured in nuclear
extracts using NF-kB (p65) Transcription Factor Assay kit
(Cayman Chemical Company). In brief, cells were lysed in a
hypotonic buffer on ice for 15 minutes and centrifuged for 30
seconds to pellet nuclei. Then the pellet was re-suspended in
nuclear extract buffer on ice for 15 min. The lysates were
centrifuged at 14,000 6 g for 10 minutes, and supernatants
containing the nuclear proteins were collected. NF-kB activation
was measured according to the manufacturer’s instruction using
10 mg of nuclear protein per well. Following color development,
absorbance was read at 450 nm within 5 minutes.
Statistics
The results are presented as mean6SEM. Each experiment was
performed four times or more to ensure reproducibility. The
significant difference from the respective controls for each
experimental test condition was assessed by one-way analysis of
variance (ANOVA) and two-tailed Student’s t-test. The difference
is significant if the P-value is less than 0.05. Software used:Sigma-
Plot 10.0 and GraphPad Prism 5.
Figure 1. AGEs induce inflammatory signalings in human OA chondrocytes. Human OA chondrocytes (16106/ml) were incubated with
AGEs (5–100 mg/ml) for 24 hours and cytotoxic effect was determined by MTT assay (A). Productions of MMP-13 (B) and IL-6 (C) were quantified by
the ELISA kits. Protein expressions of collagen II (D) were determined by Western blotting. Densitometric analysis for collagen levels corrected to b-
actin is shown. All data are presented as mean 6 SEM for three independent experiments. *: P,0.05 versus control.
doi:10.1371/journal.pone.0066611.g001
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Results
AGEs induce inflammatory responses in human OA
chondrocytes
Human OA chondrocytes were treated with increasing doses of
AGEs (5, 25, 50, and 100 mg/ml) for 24 hours and no significant
cytotoxic effect was found as compared with normal control or
BSA control (Figure 1A). AGEs effectively induced the productions
of MMP-13 and IL-6 (Figures 1B and 1C) and resulted in the
reduction of collagen II expression (Figure 1D) in a dose-
dependent manner. Moreover, AGEs significantly up-regulated
the expressions of COX-2 (Figures 2A and 2B) and HMGB1
(Figures 2C and 2D) in a dose- and time-dependent manner. On
the other hand, AGEs (50 mg/ml) markedly induced the
phosphorylations of IKKa/b, IkBa, and NF-kB p65 (Figure 3A,
3B and 3C) and the degradation of IkBa (Figure 3B) and the
translocation of NF-kB p65 from cytosol to nucleus (Figure 4A and
4B) in a time-dependent manner. Also, AGEs could significantly
activate NF-kB activity. (Figure 4D). Pretreatment with NF-kB
inhibitor PDTC (20 mM) could effectively reverse the reduction of
collagen II expression induced by AGEs (Figure 3D). These results
indicate that AGEs are capable of inducing inflammatory
signalings and reducing collagen II expression in human OA
chondrocytes.
Involvement of TLR4 and RAGE in AGEs-increased
inflammatory responses in human OA chondrocytes
It has been reported that TLR4 and RAGE are presented in
articular cartilage and are increased with aging and OA [25,26].
We next investigated whether RAGE and TLR4 are involved in
AGEs-induced increase of inflammatory responses in human OA
chondrocytes. With AGEs (5–100 mg/ml) treatment, the expres-
sions of TLR4 (Figures 5A and 5B) and RAGE (Figures 5C and
5D) were up-regulated in a dose- and time-dependent manner.
Moreover, pretreatment with neutralizing antibodies for TLR4
and RAGE could effectively suppress the AGEs (50 mg/ml)-
increased COX-2 (Figures 5E and 5F) and HMGB1 (Figures 5G
Figure 2. AGEs induce inflammatory signalings in human OA chondrocytes. Human OA chondrocytes (16106/ml) were incubated with
AGEs (5–100 mg/ml) for 24 hours (A, C) or 0.5–24 hours (B, D). Protein expressions of COX-2 (A, B) and HMGB1 (C, D) were determined by Western
blotting. Densitometric analysis for COX-2 and HMGB1 levels corrected to a-tubulin is shown. All data are presented as mean 6 SEM for three
independent experiments. *: P,0.05 versus control.
doi:10.1371/journal.pone.0066611.g002
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and 5H) expressions. Quentification and statistical analysis were
performed in Figure 6. These results indicate that TLR-4 and
RAGE are involved in the AGEs-up-regulated COX-2 and
HMGB1 expressions in human OA chondrocytes.
AGEs down-regulate PPARc expression via TLR4 and
RAGE in human OA chondrocytes
Previous evidence suggested that PPARc plays a crucial role in
the development of OA progression [27]. The decreased
expression of PPARc in OA cartilage might result in the increased
inflammatory and catabolic responses [21]. We next tested
whether AGEs affect the expression of PPARc and the involve-
ment of TLR4 and RAGE in human OA chondrocytes. AGEs (5–
100 mg/ml) effectively decreased the expression of PPARc in a
dose- and time-dependent manner (Figures 7A and 7B). Chon-
drocytes pretreated with NF-kB inhibitor PDTC showed no effect
on AGEs-induced down-regulation of PPARc expression (Figure
4C). Moreover, pretreatment with neutralizing antibodies for
TLR4 and RAGE could effectively suppress the AGEs (50 mg/ml)-
decreased PPARc expression (Figures 7D and 7E). These results
indicate that TLR-4 and RAGE are involved in the AGEs- down-
regulated PPARc expression in human OA chondrocytes.
PPARc agonist pioglitazone reverses the AGEs-increased
inflammatory responses in human OA chondrocytes
We next evaluated the effect of PPARc agonist pioglitazone on
AGEs-increased inflammatory responses in human chondrocytes.
As shown in Figure 8, pioglitazone (10 and 50 mM) significantly
reversed the AGEs (50 mg/ml)-increased MMP-13 (Figure 8A) and
IL-6 (Figure 8B) productions. Moreover, AGEs-induced COX-2
and HMGB1 expressions could also be inhibited by pioglitazone
(Figure 8C and 8D). Pioglitazone also inhibited the AGEs-down-
Figure 3. AGEs activate NF-kB signaling in human OA chondrocytes. Human OA chondrocytes (16106/ml) were incubated with AGEs (50 mg/
ml) for indicated time intervals. The phosphorylations of IKKa/b (A), IkBa (B) and p65 (C) and the degradation of IkBa (B) were determined by Western
blotting. In D, Chondrocytes were pretreated with PDTC (20 mM) for 1 hour followed by treatment with AGEs for 2 hours. Protein expression of
collagen II was determined by Western blotting. Densitometric analysis for p-IKKa/b, p-IkBa, IkBa, p-p65, and collagen II levels corrected to a-tubulin
is shown. All data are presented as mean 6 SEM for three independent experiments. *: P,0.05 versus control. #: P,0.05 versus AGEs alone.
doi:10.1371/journal.pone.0066611.g003
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Figure 4. AGEs activate NF-kB activity in human OA chondrocytes, which can be reversed by pioglitazone. Human OA chondrocytes
(16106/ml) were incubated with AGEs (50 mg/ml) for indicated time intervals. The expressions of nuclear p65 (A) and cytosol IkBa degradation (B)
were determined by Western blotting. In C, chondrocytes were pretreated with PDTC (20 mM) for 1 hour followed by treatment with AGEs for
2 hours. Protein expression of PPARc was determined by Western blotting. Densitometric analysis for nuclear p65, cytosolic IkBa, and PPARc levels
corrected to Histone H1, a-tubulin, and b-actin, respectively, is shown. In D, chondrocytes (16106/ml) were pretreated with pioglitazone (10 and
50 mg/ml) for 1 hour followed by stimulating with AGEs (50 mg/ml) for 24 hours. NF-kB activity was measured using NF-kB (p65) Transcription Assay
kit and quantified with a spectrophotometric plate reader at wavelengths of 450 nm. All data are presented as mean 6 SEM for three independent
experiments. *: P,0.05 versus control. #: P,0.05 versus AGEs alone.
doi:10.1371/journal.pone.0066611.g004
AGEs Downregulate Chondrocyte PPARc via TLR4/RAGE
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e66611
regulated collagen II expression (Figure 8E). On the other hand,
the AGEs-increased NF-kB activity could be decreased by
pioglitazone (Figure 4D). These results provide the further
evidence that PPARc down-regulation is involved in the AGEs-
induced inflammatory signalings and collagen II reduction in
human OA chondrocytes.
Involvement of MAPK signaling in AGEs-induced PPARc
down-regulation
MAPK signaling pathway has been shown to be involved in the
AGEs-induced IL-6 and IL-8 expressions in chondrocytes [9]. We
next investigated whether MAPK signaling is involved in the
AGEs-mediated PPARc down-regulation and collagen II reduc-
tion in human OA chondrocytes. AGEs (50 mg/ml) effectively
increased the phosphorylations of JNK and p38MAPK in a time-
dependent manner (Figures 9A and 9B). Pretreatment with
SP600125 (a selective inhibitor of JNK) and SB203580 (a specific
inhibitor of p38MAPK) effectively reversed AGEs-induced PPARc
down-regulation and collagen II reduction (Figure 9C). Moreover,
AGEs (50 mg/ml) slightly increased the phosphorylation of ERK
at 0.5 h after AGEs treatment (Figure 10A). However, PD98059
(an ERK inhibitor) could not affect the AGEs-induced PPARc
down-regulation (Figure 10B) and collagen II reduction (Figure
10C). These results indicate that MAPK signaling including JNK
and p38MAPK is involved in the AGEs-mediated PPARc down-
regulation and collagen II reduction in human OA chondrocytes.
Figure 5. Involvement of TLR4 and RAGE in AGEs-induced COX-2 and HMGB1 protein expressions in human OA chondrocytes. In A-
D, human OA chondrocytes (16106/ml) were treated with AGEs (5–100 mg/ml) for 24 hours (A, C) or 0.5–24 hours (B, D). Protein expressions of TLR4
(A, B) and RAGE (C, D) were measured by Western blotting. In E–H, human OA chondrocytes (16106/ml) were pretreated with neutralizing antibodies
of TLR4 (20 mg/ml) and RAGE (10 mg/ml) for 1 hour followed by treatment with AGEs (50 mg/ml) for 24 hours. Protein expressions of COX-2 (E, F) and
HMGB1 (G, H) were determined by Western blotting. Results shown are representative of at least three independent experiments.
doi:10.1371/journal.pone.0066611.g005
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Discussion
AGEs are a group of compounds that are formed mainly via the
Maillard reaction, which happens when reducing sugar reacts with
macromolecules such as amino acids in proteins, lipids or DNA in
a non-enzymatic way. Several studies suggested that accumulation
of AGEs may be a mechanism for the age-related development of
OA [5–7]. In patients with focal degeneration of cartilage, the
increased levels of AGEs have been found in their healthy cartilage
[28]. Moreover, AGEs formation has also been shown to be
accelerated in diabetic patients [29]. Diabetes has recently been
suggested to be an independent risk factor for OA [30,31].
Previous studies have shown that PPARc signaling plays a potent
anti-inflammatory role by negatively regulating the expressions of
several pro-inflammatory genes [18,19]. Several studies have also
found that PPARc agonists can reduce the expression and
synthesis of cartilage degradation products in vitro and in vivo,
and suggested that activation of PPARc is capable of reducing the
progression of OA [22,20,27,32]. In the present study, we
demonstrated for the first time that AGEs down-regulate the
PPARc expression and induce the productions of IL-6 and MMP-
13, which result in the reduction of the expression of type II
Figure 6. Densitometric analysis for TLR4, RAGE, COX-2, and HMGB1 levels. Values are corrected to a-tubulin or b-actin levels. All data are
presented as mean 6 SEM for three independent experiments. *: P,0.05 versus control. #: P,0.05 versus AGEs alone.
doi:10.1371/journal.pone.0066611.g006
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collagen (major cartilage matrix macromolecules) in human OA
chondrocytes. PPARc agonist pioglitazone significantly inhibited
the productions of IL-6 and MMP-13 and reversed the reduction
expression of collagen II. These results suggest that PPARc
signaling plays an important role in AGEs accumulating human
OA chondrocytes.
The maintenance of structural and functional integrity of
articular cartilage is known to depend on the balance between
catabolic and anabolic of matrix components. The doublet effects
of AGEs on synthesis and degradation of matrix constituents
implicate that extracellular matrix turnover in articular cartilage is
affected by accumulation of AGEs [33]. Of various types of
collagens, type II collagen is related to build up the structural
Figure 7. AGEs down-regulate PPARc protein expression in human OA chondrocytes. Human OA chondrocytes (16106/ml) were treated
with AGEs (5–100 mg/ml) for 24 hours (A) or 0.5–24 hours (B). In C and D, human OA chondrocytes were pretreated with neutralizing antibodies of
RAGE (10 mg/ml; C) and TLR4 (20 mg/ml; D) for 1 hour and then stimulated with AGEs (50 mg/ml) for 24 hours. PPARc protein expression was
measured by Western blotting. Densitometric analysis for PPARc level corrected to b-actin is shown. All data are presented as mean 6 SEM for three
independent experiments. *: P,0.05 versus control. #: P,0.05 versus AGEs alone.
doi:10.1371/journal.pone.0066611.g007
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backbone of the extracellular matrix in human articular cartilage
[34]. The degradation of collagen II by interstitial collagenases,
MMPs, has been demonstrated to be a crucial step resulting in the
destruction of the joints in OA patients [35]. MMP-13 (collage-
nase-3) is an important enzyme that preferentially cleaves collagen
II in OA cartilage [35]. Moreover, IL-6 and HMGB-1 are two
important mediators of inflammation. IL-6 is a multifunctional
cytokine with a wide range of biological activities, including
mediation of acute-phase responses and effects on bone metab-
olism [36]. Patients with OA exhibits elevated IL-6 levels [36].
HMGB-1 is a ubiquitous cytokine acting as a potent promoter of
inflammation. HMGB-1 has been considered to be an important
Figure 8. Effects of pioglitazone on inflammatory signalings in human OA chondrocytes. Human OA chondrocytes (16106/ml) were
pretreated with pioglitazone (10 and 50 mg/ml) for 1 hour followed by stimulating with AGEs (50 mg/ml) for 24 hours. Productions of MMP-13 (A) and
IL-6 (B) were quantified by specific ELISA kits. Protein expressions of COX-2, HMGB1, and collagen II were determined by Western blotting (C).
Densitometric analysis for COX-2, HMGB1, and collagen II levels corrected to b-actin is shown. All data are presented as mean 6 SEM for three
independent experiments. *: P,0.05 versus control. #: P,0.05 versus AGEs alone.
doi:10.1371/journal.pone.0066611.g008
AGEs Downregulate Chondrocyte PPARc via TLR4/RAGE
PLOS ONE | www.plosone.org 10 June 2013 | Volume 8 | Issue 6 | e66611
trigger of arthritis [37]. It has also been reported that HMGB-1 is
involved in the pathogenesis of cartilage destruction in OA [38]. In
the present study, the results showed that AGEs not only induce
the productions of MMP-13 and IL-6 and the reduction of
collagen II, but also increase the expressions of COX-2 and
HMGB-1 in human OA chondrocytes in a dose- and time-
dependent manner. In addition, PPARc agonist pioglitazone
could also effectively reverse these AGEs-induced effects in human
chondrocytes, indicating that AGEs interfere with the extracellular
matrix turnover in cartilage may through a down-regulation of
PPARc.
TLRs are known to evolutionarily recognize the conserved
products unique to microbial metabolism involved in innate
immune responses and the pathology of a number of inflammatory
diseases [39]. Previous study has revealed that TLR4 is capable of
regulating the early onset of joint inflammation and cartilage
Figure 9. Involvement of MAPK signaling in AGEs-induced PPARc down-regulation and reduction of collagen II expression. Human
OA chondrocytes (16106/ml) were incubated with AGEs (50 mg/ml) for 0.5–24 hours (A, B) or 24 hours (C). The phosphorylations of JNK (A) and
p38MAPK (B) were determined by Western blotting. In C, chondrocytes were pretreated with SP600125 (10 and 20 mM) or SB203580 (1 and 10 mM) for
1 hour followed by treatment with AGEs for 24 hours. Protein expressions of PPARc and collagen II was determined by Western blotting.
Densitometric analysis for p-JNK, p-p38MAPK, PPARc, and collagen II levels corrected to JNK, p38MAPK, b-actin, and b-actin, respectively, is shown. All
data are presented as mean 6 SEM for three independent experiments. *: P,0.05 versus control. #: P,0.05 versus AGEs alone.
doi:10.1371/journal.pone.0066611.g009
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destruction in a murine model of immune complex-mediated
arthritis [40]. On the other hand, RAGE is a member of the
immunoglobulin superfamily and involved in homeostasis, devel-
opment, and inflammation. RAGE interacts with diverse ligands,
including AGEs, several members of the S100 protein family, and
HMGB1, which has been shown to be present in articular
cartilage [8,41]. Increased expression of RAGE has been
suggested to be related to various acute and chronic inflammatory
diseases including OA [42]. A recent report has shown that both
TLR and RAGE signaling systems are activated in preterm birth
and suggested that the interactions between TLR-mediated acute
inflammation and RAGE-mediated chronic inflammation may
contribute to increase the preterm birth risk [43]. The study of
Qin et al. has also suggested that the cross-talk between TLR4 and
RAGE contributes an increase in inflammatory signalings in
macrophages [44]. In the present study, we used neutralizing
antibodies for TLR4 and RAGE to investigate the roles of TLR4
and RAGE in AGEs-induced inflammatory signalings in human
OA chondrocytes. Our data showed that AGEs can up-regulate
both TLR4 and RAGE expressions in a dose- and time-
dependent manner. Both neutralizing antibodies for TLR4 and
RAGE effectively suppressed the AGEs-increased COX-2 and
Figure 10. ERK signaling is not involved in the effects of AGEs on chondrocytes. Human OA chondrocytes (16106/ml) were incubated with
AGEs (50 mg/ml) for 0.5–24 hours (A) or 24 hours (B,). The phosphorylation of ERK (A) were determined by Western blotting. In B and C, chondrocytes
were pretreated with PD98059 (10 and 20 mM) for 1 hour followed by treatment with AGEs for 24 hours. Protein expressions of PPARc and collagen II
was determined by Western blotting. Densitometric analysis for p-ERK, PPARc and collagen II levels corrected to ERK, b-actin, and b-actin,
respectively, is shown. All data are presented as mean 6 SEM for three independent experiments. *: P,0.05 versus control.
doi:10.1371/journal.pone.0066611.g010
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HMGB-1 expressions and reversed the AGEs-induced PPARc
down-regulation. These findings indicate that both TLR4- and
RAGE-mediated inflammatory signalings implicate in the AGEs
accumulation-related OA pathogenesis.
TLR ligands have been found to be capable of leading the
activations of MAPKs and NF-kB in chondrocytes [45]. Several
studies have shown that MAPKs signals (p38, JNK, and ERK) are
activated and involved in the increased inflammatory signalings
and MMPs expressions in AGEs (100–400 mg/ml)-treated chon-
drocytes [9,46,47]. In these studies, the authors found that
SB202190 (p38 inhibitor) could inhibit the AGEs-induced
responses in chondrocytes; however, the effects of SP600125
(JNK inhibitor) and PD98059 (ERK inhibitor) are controversial
[9,46,47]. In the present study, we have found that AGEs (50 mg/
ml) markedly enhance the phosphorylations of JNK and
p38MAPK, but induce a slight and transient increase in ERK
phosphorylation, in human OA chondrocytes. Specific inhibitors
of JNK and p38MAPK, but not ERK, effectively inhibited AGEs-
induced down-regulation of PPARc and the reduction of collagen
II. These results suggest that JNK and p38MAPK are involved in
the AGEs-mediated down-regulation of PPARc in human OA
chondrocytes. This finding is consistent with the findings in IL-1b-
treated human chondrocytes [21] as well as AGEs-treated rabbit
chondrocytes [24]. Besides, we have also found that PDTC, a NF-
kB inhibitor, is capable of inhibiting the AGEs-induced reduction
of collagen II expression, but can not abolish the AGEs-induced
PPARc down-regulation in human OA chondrocytes. Moreover,
pioglitazone could decrease the AGEs-increased NF-kB activity
and collagen II reduction. These findings suggest that the
destruction of collagen II by AGEs in human OA chondrocytes
may be through a JNK/p38MAPK-activated PPARc down-
regulation-triggered NF-kB activation signaling pathway.
In conclusion, as indicated in Figure 11, our results demon-
strated for the first time that AGEs induce the inflammatory
signalings, productions of MMP-13 and IL-6, and collagen II
reduction in human OA chondrocytes via a TLR4 and RAGE-
regulated p38MAPK/JNK-activated PPARc down-regulation-
triggered NF-kB activation signaling pathway. In addition, these
findings implicate that the accumulation of AGEs is correlated to
the erosion of human OA cartilage and stimulates chondrocytes to
produce more catabolic factors (MMPs and cytokines) and less
anabolic factors (collagen II). The TLR4 and RAGE-regulated
down-regulation of PPARc is important in the net catabolic effect
of AGEs on cartilage and may play a crucial role in the
development of OA pathogenesis induced by AGEs accumulation.
The clinical significance of these findings needs to be clarified in
the future.
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